News & Updates
Showing Oncology articles
Showing
Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
Pathological response rates are high for neoadjuvant dabrafenib plus trametinib among patients with stage III melanoma, but recurrence-free survival (RFS) rates are low, reports a study.
Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
12 Aug 2024
First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC
First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.
First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC
12 Aug 2024
Cabozantinib offers survival benefits to ICI-treated HCC patients
A phase II trial of cabozantinib demonstrates the study drug’s efficacy in patients with hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitor (ICI) regimens.
Cabozantinib offers survival benefits to ICI-treated HCC patients
11 Aug 2024
Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma
In patients with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy (LOT), treatment with belantamab mafodotin (belamaf) plus pomalidomide and dexamethasone (BPD) results in statistically significant and clinically meaningful progressive-free survival (PFS) compared with pomalidomide plus bortezomib and dexamethasone (PVD), as shown in the DREAMM-8 study.
Belamaf plus pomalidomide/dexamethasone improves PFS in relapsed multiple myeloma
08 Aug 2024
Cabozantinib and SBRT: Two feasible post-IO strategies in HCC
Liver cancer is a major cause of death globally and in Hong Kong. Both first- and second-line treatment of the disease have evolved considerably over recent years, following the approval of immune checkpoint inhibitors (ICIs). At present, over half of hepatocellular carcinoma (HCC) patients require second-line treatment, yet data on therapies administered after immunotherapy are lacking. This article summarizes locally reported findings on use of cabozantinib and stereotactic body radiotherapy (SBRT) in HCC patients who progressed on immunotherapy.